Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of hypoglycemic agents on peripheral T-lymphocyte subsets in patients with type 2 diabetes
ChiCTR-OPN-17010405Phase 4Recruiting
- Sponsor
- Nanjing First Hospital
- Start
- Jan 2017
- Modality
- Small Molecules, Microbiome-Derived Products → Microbiome Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of human insulin, metformin and acarbose in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Nanjing First Hospital. Primary endpoints: Regulatory T cells (Treg), T helper 1 (Th1) cells and 3 more. Started Jan 2017; status: recruiting.
02
Drugs
human insulinmetforminacarbose
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR-OPN-17010405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPN-17010405.